Investigating how walnuts and gut bacteria affect colon cancer risk
Microbiota, Metabolites, and Colon Neoplasia
This study is looking at how eating walnuts might help lower the risk of colon cancer by changing the bacteria in your gut and producing a helpful compound called Urolithin A, and it's for people aged 45 to 75 who want to learn more about how their diet can affect their health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Connecticut Sch of Med/dnt NIH-funded |
| Lab location | 1 site (Farmington, United States) |
| Project ID | NIH-11094770 on NIH RePORTER |
What this research studies
This research explores the relationship between walnut consumption, gut microbiota, and the risk of colon cancer. It focuses on a compound called Urolithin A, which is produced by gut bacteria from walnuts and is believed to have anti-cancer properties. The study will involve a randomized, controlled trial with participants aged 45-75 to assess how walnut supplementation influences cancer risk factors and the production of Urolithin A. By understanding individual differences in Urolithin A production, the research aims to identify potential biomarkers for cancer prevention.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 45-75 who are interested in dietary interventions for cancer prevention.
Not a fit: Patients who are not within the age range of 45-75 or those who do not consume walnuts may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to dietary recommendations that significantly reduce the risk of colon cancer.
How similar studies have performed: Previous research has shown promising results regarding the cancer-preventive properties of dietary polyphenols, making this approach both relevant and potentially impactful.
Where this research is happening
Farmington, United States
- University of Connecticut Sch of Med/dnt — Farmington, United States (Active)
Researchers
- Principal investigator: Rosenberg, Daniel William — University of Connecticut Sch of Med/dnt
- Study coordinator: Rosenberg, Daniel William
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.